Arthur & Beatrix

Our diversity series is here! Today we would like you to meet Arthur and Beatrix. This article is very special for us because they are a source of inspiration at HEMEX. Arthur is from Scotland and Beatrix from Switzerland. Both are very talented professionals that have worked hard to be where they are now. Two team leaders with endless knowledge about the industry. At HEMEX, we are very honored to count them in our team. Would you like to know a little more about them? Just keep scrolling!

 

               Arthur

 

“Never give up”

 

 

Arthur is a Veterinary Surgeon by training. He was born in The Borders of Scotland, and he grew up on a farm as his family owned an agricultural business. This helped him decide very early on his life that he wanted to become a veterinary surgeon.

However, sometimes the pathway to your desired dream is not easy, and gaining support is difficult. Arthur was told many times that getting into vet school was too hard and that he would not succeed. This is because, in the UK, Veterinary schools ask for very high academic achievements and standards. Arthur started at a very young age to develop the mantra that defines him nowadays; “When somebody tells me; you cannot do something, it’s impossible! THAT’S IT. I believe everything is possible, the difference is in the amount of work you are prepared to put in”.

Arthur had top-grades and was very keen to pursue his dream, so obviously, he was accepted at the University of Edinburgh as a veterinary student, and his performance at University was outstanding. After University, he worked for three years in general practice until he decided to start a career in the genetics industry. A once in a lifetime opportunity appeared, and Arthur knew he had to go for it. That is how, at just 26 years of age, he became the Head of Veterinary Services for the Scottish Milk Marketing Board. Arthur explains, “That’s where I started my career in corporate vet medicine work, and I worked very hard because I wanted to prove that I could do it.”

Arthur’s professional career is very impressive and inspiring. He has worked with the top veterinarians, surgeons, and KOL’s in the world. Arthur has experience in the cattle breeding genetics field, helped create the first commercial laboratory in the world to sex cattle semen, set up an IVF laboratory, and helped develop a Bovine Viral Diarrhea Virus (BVDV) vaccine. Arthur has worked at leading pharmaceutical companies. At Novartis, he commercialized one of the first bovine virus diarrhea vaccines in the world. After that, Arthur became Head of Marketing for the Veterinary Business in the UK. Then he decided he wanted to do a professional training course in Marketing, and then found that he was just born to work in this field!

Arthur arrived in Basel in 2003 and became the International Brand Manager for the cattle and sheep business. By this point, he really wanted to focus on developing his business career, but he stayed on and launched a new molecule called AHC2225, which later became Monepantel to cure any type of worm infection in animals. “The significance of this molecule was revolutionary, and it was potentially fantastic,” Arthur explains to HEMEX. Arthur tells us that the cattle and sheep category business unit was a big success story, and the business grew exponentially because he had a brilliant team working with him. 

Arthur arrived at HEMEX about a year ago. He had previously worked with some of our team members, and we asked him if he would like to work with HEMEX and bring his expertise to our team. At HEMEX, we are delighted to have someone in the team who has had such a great career.

Arthur tells us, “I have a real burning desire to give something back to my ancestors by preparing something for my successors. We stand on the shoulders of generations of people who worked very hard.” Therefore, one of the fundamental things that drives him is the commitment to humanity, justice, and fairness. “Working hard and treating people fairly and with justice is so important. Treating people for what they can bring, not what they have got.”

Arthur speaks English and German. He loves fantastic lamb dishes, great wines and cheese, and he likes to ski, hike, and play golf. We would like to finish this inspiring real-life story with a quote from Arthur, which we believe sums him up perfectly. 

“In my life, I have had so many people telling me that you can’t do this or that. But just know that, what are you trying to achieve, have that dream, and never give up, because you’ll get there.” 

As part of our diversity series, we asked Beatrix to sum up Arthur in one word. She said that for her, Arthur is HUMOROUS.

 

 

                Beatrix

 

“Everybody matters”

 

 

Beatrix is a Communications Expert by training. She was born and raised in Switzerland, while her family is originally from Austria. She grew up in Zurich, lived in Lausanne, and in the US. Beatrix has a scientific background in neuroscience with more than ten years’ experience in this field.

To expand her knowledge and skills, she decided to study Communication and Journalism as well. She tells HEMEX that she “really likes to explain complex scientific topics in a language understandable to everyone.” In neuroscience, she was fascinated by the communication between cells in the brain. Explaining these interesting aspects of the brain to people is something that she enjoys, and this motivated her to bridge the gap between Communication and Science.

Scientific journalism was a topic that interested Beatrix. However, she found that she was particularly passionate about corporate communication. She finds this very inspiring because it allows her to interact and coach companies, whilst also working alongside with the media, “but the game-changer was that I like to be part of a team, to work together with other people towards a common vision.” She is a team worker, and at HEMEX, we appreciate this very much because she makes our work very easy!

Beatrix started to work as a Communications Manager at Novartis Animal Health (now Elanco), where she mainly dealt with internal communication. She was then offered an important role as a Global Communications Manager at Novartis Group. This was not an easy move because she really loved working in the animal health industry, together with a great team. However, she tells us, “It is important to understand and experience different dynamics and companies to grow professionally.” That was also why she decided to join Nycomed (now part of Takeda) as Director of Media Relations. During this experience, she strengthened her professional expertise and oversaw the foundation of media relations for the company. For almost three years, hard work allowed her to build a name for the company and get known by journalists and the media.

Beatrix already had a brilliant professional career when she was recruited as Head of Global Communications & Public Affairs for Vifor Pharma. She saw this as a great opportunity and immersed herself in this new and stimulating adventure. She built up the Communication Department from scratch: internal, external, and online communications, crisis management, media relations, and a completely new branding in preparation of the public listing of the company.

After almost 7 years, Beatrix joined a Biotech company in Lausanne. She enjoyed moving back to the Lake Geneva region as this allowed her to refresh her French and work in the Biotech industry. She improved the business and communication strategy for almost one year, and in 2019, she decided to start her own business.

Her company is currently a well-known reference point for established pharma, and small pharmaceuticals like Biotech and MedTech start-ups that need support with media and communication. In this context, Beatrix had the pleasure of meeting the HEMEX team, and since last summer, we are extremely happy to work alongside with her.

Even if her agenda is always full, Beatrix enjoys spending time with her family. During their free time, they enjoy their dinners together, traveling to new places, and sailing. In fact, Beatrix’s favorite dishes are anything that her husband cooks. Beatrix speaks German, English, and French. She believes that everybody is important and has something to teach and share. We would like to finish this inspiring real-life story with a quote from Beatrix, which we believe sums her up perfectly.

“For me, it is key, not just professionally but also personally, to ensure that everybody matters. I really try to respect that, it does not matter the title or the hierarchy, everybody is important when you are contributing to success.”

As part of our diversity series, we asked Franziska to sum up Beatrix in one word. She said that for her, Beatrix is ENTHUSIASTIC.

 

About HEMEX

HEMEX was founded as a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. We specialize in supporting early-stage start-ups, and we offer tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. We are now gaining fast recognition, and this is partly because we are transforming the culture by seamlessly bridging the gap between investors and entrepreneurs.

A Future-Oriented Loan For Inura

Congratulations to our portfolio company Inura for being selected for the loan “100 fürs Baselbiet” from BLKB. Inura will receive a total of 500,000 CHF!

 
“100 fürs Baselbiet” is an initiative organized by BLKB, the University of Applied Sciences Northwestern Switzerland FHNW, and the Baselland Economic Development Agency. This future-oriented program facilitates access to financial resources as well as advisory services for innovative SMEs and start-ups related to the Basel area.
 
The “100 fürs Baselbiet” purpose is based on strong collaborations between industry, science, and government. The goal is to help SMEs and start-ups to expand. Besides, this initiative intends to enhance the attractiveness and innovative capabilities, create jobs, and add economic value to the region. Interested companies have gone through a two-stage selection process. First, you submit your business idea with the associated financial plan. Afterward, if there is positive feedback, an independent advisory board assesses the companies’ applications pre-selected in so-called pitches. Subsequently, the Advisory Board decides which ideas and companies will receive support. 
 
The selected companies receive financing in the form of loans from BLKB. Obtaining this loan indicates the confidence that the Advisory Board has in the project and the team. The criteria are, among other things, the innovative strength and sustainability of the ideas presented and the quality of the entrepreneurial team. At HEMEX, we believe as well on Inura’s project and its team. Therefore, we are thrilled to see them acomplishing this achievement.
 
Inura Medical AG logoInura Medical is developing an innovative urethral suppository for women with Overactive Bladder Syndrome (OAB). This highly prevalent and disabling health disorder has a significant impact on 20% of the female population’s quality of life. For instance, sleep deprivation, fatigue, nocturia, or memory lapses. Unfortunately, around 70-90% of the patients discontinue the available treatments because of their side effects. Inura Medical’s new, patented design suppository facilitates the effective penetration of drugs through the urethral mucosal lining. This new route of administration has greater therapeutic efficacy, and there are fewer side effects. Moreover, Inura Medical’s technology will reduce healthcare costs related to the treatment of OAB. Thanks to its partnership with HEMEX, Inura can complete an entire development program until Phase 3 in which the effects of the oral and urethral administration of the drug will be compared.
 
Hemex has a strong track record in women’s health and we immediately saw the potential of Inura’s urethral suppository platform. If you would like to know more about Inura, check their website HERE.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Ready To Battle?

Innosuisse will select the top 15 Swiss Startups with the most sustainable solution that positively impact the climate, society, and the greater good for their Digital Day 2020

 

The fourth edition of the nationwide Swiss Digital Days with activities in locations across Switzerland will have place from the 1st– 3rd of November. As a start-up, you will have the opportunity to enhance your dialogue with the swiss public, politicians, science, and civil society. Apply for the Start-up Battle and let’s experience digital together!

 

 

How does it work?

Out of all applications, digitalswitzerland and Startup INVEST selects 15 Start-ups. These 15 Start-ups are asked for a video (max. 3min) where they pitch their impact.

The video will be shared on the digital day website and the public will be allowed to vote for the Public award.

Afterwards, the Jury will select the 5 finalists. These 5 finalists will pitch live in front of a jury at SRF Studios. Finally, the Jury will award a prize to the 3 most innovative start-ups that generate a sustainable impact.

 

What’s in it for you?

5k in cash, for the winner, and more prices to follow.

 

Important! Start-up selection criteria

-Sustainable impact on climate, society, and the greater good
-Market Potential (problem/solution fit)
-Business Model
-Team
-Innovation (IP, Magic Sauce)

 

If you are looking for funding and visibility don’t miss this opportunity. Complete and submit the form below BEFORE 30.09.2020 including the upload of your video pitch and slides. Do you need help with your Pitch Deck and Video? We can help you, contact us here: yaozi.moreno@hemex.ch

To apply directly HERE.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Hemex Organizes Thriving Online Pitch Event

Magnes, denovoMATRIX, Bionomous, Sleepiz, and Sedimentum pitched their ventures at the HEMEX incubator to an online group of renowned international investors.

 

HEMEX has been organizing since June online Pitch Events to ensure safety for all participants. This time, the focus was directed to start-ups that are currently developing solutions to help transform health care with their breakthrough innovations. At Hemex our objective is to organize Pitch Events where selected start-ups get the opportunity to pitch in front of potential investors, and investors get the opportunity to ask them questions. Therefore facilitating the contact to speed up prosperous collaborations.

As a special guest, David C.Sutter, Program Manager of 100 fürs Baselbiet of BLKB, joined us today at our headquarters in Liestal, “It was a very interesting chance to get to know different companies, to have a first impression about their business models, and learn about their teams”, David tells to Hemex. “This kind of events are a great possibility for start-ups and investors to bring them together and have a first contact”. 1004BB promotes access to financial resources and coaching. Addressed are start-ups and small & medium enterprises (SMEs) that are related in the greater Baselland Area, either being incorporated in the region or that are expected to bring added value to the greater region.

 

Today’s event kicked off with the start-up Magnes AG. Cofounders Dr. Olgac Ergeneman and Dr. George Chatzipirpiridis, CEO and COO at Magnes respectively, presented their disruptive real-life-monitoring solution to analyze walk patterns of patients with neurological disorders. Magnes has developed a technology that, using smart sensors embedded in sneaker-like shoes, data is collected from patients during their daily activities. Their AI processes data to generate automatic reports and provide the patient with direct feedback preventing situations like freezing of gait. “We have tested our product on patients and we proved that it’s working. We are excited to see the positive reactions from patients. Helping them to improve their lifes it’s a completely different level of happiness. Now we need funding to upscale it and reach a bigger number of patients” explains George to Hemex. “Is very motivating to be able to make a change in patients’ lifes, and it’s not just about the business or the funding, seeing that you can really help someone is the big motivation” adds Olgac. Magnes’ technology can change the way clinical trials are performed today and improve efficacy by enabling data-driven therapy through tailored medication dosage.

 

The second start-up pitching at our event was denovoMATRIX. Dr. Dejan HušmanCEO & Cofounder of denovoMATRIX, presented their innovative idea. denovoMATRIX GmbH enables cell-based therapies’ acceleration through its proprietary biomaterial platform, which addresses bottlenecks in cell manufacturing. They are redefining cell culture in life science and offer modular, biomimetic coatings for cell culture plastic ware that can be tailored to recreate a large variety of extracellular matrices (ECM) for any adherent cell culture. “We believe that the significance of cell-based therapies will grow in the future, therefore manufacturing these therapies is the absolute key to successful implementation,” explains Dejan to Hemex “this is the first Pitch Event that I have taken part where there is enough time for the start-ups to pitch in a more relaxed environment. You have time to be asked questions about your project and go into more specifics with investors“. The biomaterials space is an overlooked niche, and their enabling technology will prove invaluable to key cell therapy players, making them an attractive investment.

 

 

The third start-up pitching was Bionomous. Cofounders Frank Bonnet and Ana Hernando Ariza, CEO and CMO of Bionomous respectively, presented their innovative solution. Bionomous is developing and commercializing a cost-effective robotic device that automatically carries out the screening, sorting, and dispensing of miniature biological entities, such as the zebrafish embryos, a model growing in popularity in toxicology, genetics, and cancer research. “We want to automatize the process that are using the zebrafish model, and this will not only help accelerate research but also reduce animal experimentation” tells Frank to Hemex. “The zebrafish is indeed an alternative model to reduce animal experimentation, as research can be made using the eggs and embryos, which are not considered as animals due to their very early age.” Ana also adds “With automation you also standardize the whole process. You can save a lot of mistakes and misunderstandings done in the lab and in the end you save time and money”. Their patented technology offers thus a portable and affordable solution for laboratories working intensively with the zebrafish.

 

The forth start-up pitching at our event was Sleepiz. Max Sieghold, CFO and Cofounder of Sleepiz, presented their innovative idea. Sleepiz is aiming to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable solution with a device that is simply placed on the bedside table. “We are adressing a huge market, because we are in a time point where digital health solutions for monitoring patients are really required. There is a strong need because such a huge population is affected, but we don’t have any solutions that are viable” explains Max to Hemex after his presentation. “A lot of healthcare providers have realized that from a patient side there is a need to be monitored at home. We really see the market is ready, and the market wants a solution like ours”. By using wireless millimeter wave technology, sensor fusion, and artificial intelligence, Sleepiz will not only diagnose sleep disorders but also perform long-term monitoring.Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.

 

Sandro Cilurzo, CEO of Sedimentum, presented their startup which developed the first contactless solution for fall and emergency detection in healthcare, without compromising privacy. Sedimentum‘s technological protection solution ensures the physical safety of unattended people, in a complete automated and contactless manner with a strong focus on human data privacy. “We are deeply convinced that our solution will make the lives of thousands of people safer and more autonomous in the future. With our unique technology and our ambitious team, we want to disrupt the healthcare market and make living safe.” explains Sandro to Hemex. “This great pitching event gave us the opportunity to present our vision and mission to potential investors”. Sedimentum supports and relieves the burden on nursing staff, who are informed in real-time about falls and health threatening events of their patients.

 

Many thanks to Olgac, George, Dejan, Frank, Ana, Max and Sandro for introducing us to their unique ideas and solutions. We wish you good luck with your projects!

Are you interested in becoming an early-stage investor in one of these promising start-ups? Would you like to receive a personalized invitation to one of our next sessions?

Or are you interested in learning about how to create a great pitch deck that excites potential investors about your idea?

Then you are in the right place! Contact our start-up coach Franziska Stemmler for more information.

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX

Schools with a clear mission

Community commitment should be something essential in every company that wants to make a difference in society. Here’s our suggestion to how you can help your community in Liestal

 

Hemex supports educational programs with a long-term positive impact. The SOL School for Open Learning emerged from the Freie Volksschule Basel (FVB). It was founded in 1982, and since 2000 is located in Liestal. With twenty years of experience, SOL’s basic attitude is the loving respect for life processes. When children and young people experience this basic attitude and adopt it for themselves, they acquire something necessary for the current times we live in: sustainability.

Sustainability as the process of maintaining a balance between the environment, the economy, and the social domain. Therefore, in SOL, not just the children and the young people, but also adults learn from each other and develop their vital forces to be part of a comprehensive whole. The aim is to contribute to a peaceful, solidary, and individual respecting society by promoting a sense of responsibility for the community and the ability to criticism and tolerance.

 

 

This unique school defines, assesses, and appreciates the performance of each student individually. In doing so, it takes into account the whole spectrum of human beings. Different forms of expression are considered, and both intellectual and artistic practical activities are reinforced.

If you would like to know more about SOL. The upcoming Info-Tag will be next Saturday 19th September, from 10 am – 15 pm at HANRO Areal, Liestal. For more information visit their website HERE.

 

 About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

BioReperia gains international recognition!

BioReperia has recently joined an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

 

We are delighted to announce that our portfolio company BioReperia has taken part in an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

RISE program connects organizations from the academic and non-academic sectors (in particular SMEs). By linking research and personnel, and sharing expertise and ideas between the innovation research field to the market field, RISE facilitates international and multisectoral cooperation. The scheme promotes a shared research and innovation culture that embraces and recognizes creativity and entrepreneurship.

This grant will help BioReperia to progress and advance their technology (zebrafish ZTX-platforms) towards IVD-precision medicine and drug discovery. The program offers assistance thought collaborative research and the development of innovation for the project. The objective is to share knowledge via international and intersectoral mobility, based on research and innovation staff allocation with an in-built return mechanism.

BioReperia’s innovative technology will shed light on immune-oncology, specifically how dysregulation in cysteine leukotriene signaling contributes to cancer development.

 

About BioReperia

BioReperia AB is a privately-owned contract research organization (CRO) founded in September 2015 based on technology developed at Linköping University in Sweden. Their technology is used to accelerate drug discovery and individual test treatments on specific patients in clinical trials. They are active as a CRO in the European market for drug discovery in academic institutions and pharmaceutical companies. BioReperia AG was incorporated at HEMEX’s incubator on december 2019 to focus on the development of IVD to fight against different types of cancers. More info at BioReperia.

 

 About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Juan & Laurène

Today, we continue with our diversity series. In this article, please meet Juan and Laurène. Juan is from Colombia, and Laurène is from Switzerland. Would you like to know a little more about their lives and what do they do at HEMEX? They are two remarkable professionals to work with. They are the kind of people that always find a way to get the work done. For HEMEX, having them on the team makes a huge difference!

 

                 Juan

 

 

“To be first, is to be last”

 

Juan is a Graphical Designer by training. He was born in Cali, Colombia. Juan studied Advertising and Marketing, and during one of the courses in this degree, he discovered his passion for graphical design. When he was offered to go and study graphic design in the US, he quickly jumped at this fantastic opportunity.

He then moved to Iowa, US, to study an MFA in Graphical Design, and that is where he met his wife. Once he finished his studies, Juan moved to Europe with his wife and got an exciting job in the UK, working in an engineering company. In this position, Juan had a lot of responsibility and this was very challenging and rewarding for him because he builded their visual identity from 0.

Five years ago, Juan and his family moved to Switzerland, and he started working as a freelancer. Juan arrived at Hemex in a special way; one of his private clients was also a start-up working with HEMEX. Once we saw all the excellent branding, we were so impressed with his work that we directly contacted him to offer him a position at HEMEX! he is a very innovative creative designer, and we highly appreciate his work.

Juan started working at HEMEX in October last year. At HEMEX, he works in the Marketing & Communication team. He helps in our PR activities and improves our graphical design, from designing Pitch Decks and websites to creating the whole corporate identity, logo, and branding. Juan is an expert at communicating clearly and simply. “Sometimes, it is very clear for someone who has very advanced knowledge in a field to explain what they do, but then when other people try to understand it, it gets complicated. You need direct and clear information.” Juan explains that he is thrilled to be working at HEMEX, and every day is different because we work with very different start-ups. This is why it is very important to be flexible and serviceable. 

Juan is very happy that he decided to go and study in the US. He explained to us that when he left Colombia, it was not common to leave your parents’ house so early. “At the beginning, it was a little hard, you leave not just your family, but also your home country and your culture, but then you learn how to be resourceful by yourself.” We sympathize a lot on this; moving countries can provide an excellent opportunity to challenge yourself and grow both personally and professionally. Juan is very proud of where he is right now, and he is very confident in what he does. We have to say he is also outstanding!

Juan speaks Spanish, English, and Italian. He explains to us that for him, it is very important to feel useful to others, not only personally, but also professionally. He claims that it is very comforting. Obviously, family comes first, but as lifestyle, he states that serving others makes him feel good. In fact, his professional mantra is aligned with this. At HEMEX, we have experienced that because Juan always puts his interests in second place and the ones of the clients and colleagues always come first. Moreover, Juan is an excellent drum player, and in his free time, he enjoys flying. Yes, you’ve read it correctly, our amazing Juan is a pilot in his free time.

As part of our diversity series, we asked Laurène to sum up Juan in one word. She said that for her, Juan is CREATIVE.

 

 

                Laurène

 

“La différence entre le possible et l’impossible se trouve dans la détermination”

 

Laurène is a Veterinary Surgeon by training. She was born at the CHUV in Lausanne, Switzerland. She grew up in the French-speaking part of Switzerland and went to a Bilingual International school, where she studied subjects in both English and French. She tells us she did a lot of sport at school and competed in ski racing, badminton, and swimming. We could say, Laurène is the sportiest person in the HEMEX team!

Laurène is a bright woman with very clear ideas. She always knew that she wanted to be a vet. At home, she has two dogs, one of which is a rescue dog that really motivated Laurène to study veterinary medicine. Two years before applying for University, she did many placements in Veterinary practices and in the pharmaceutical industry. These placements also reinforced the fact that she wanted to study veterinary medicine and she was offered a place at Nottingham University. At University, she was part of the ‘Livesaving’ Society and taught other students first aid and rescue people drowning in the water. She admitted that she loved doing this; “It was very rewarding to teach others first aid and rescue skills because with such knowledge, they could go and really make a difference and maybe even save someone’s life”. At University, Laurène also got some of her research published in a scientific journal. It was a very interesting equine medicine research project.

In her final year at University, she completed her rotations in clinical practice. She worked in hospitals, charity clinics, and really enjoyed all the emergency work. She especially enjoyed her equine and farm rotations. Laurène always knew she wanted to work in clinical research.  Even though she enjoyed clinical practice and could make a big difference to an individual patient which was very rewarding, she always strived to make more of a global impact and this is why she decided to work in industry.

Laurène finished her studies in July, shortly before she arrived at HEMEX. We were amazed and impressed by her talent. She joined HEMEX because she wanted to broaden her horizons. “HEMEX allows me to work in the human medical field, in clinical operations and in the veterinary field, and this was a great opportunity for me”. At HEMEX, she works in the Clinical Operations team, and helps in the Business development team. She enjoys the diversity at HEMEX. The fact that she has been able to explore different areas in different fields allows her to help and make a difference.

Laurène speaks French, English, and some German. She loves skiing, hiking, swimming, badminton, horse riding… every sport is enjoyable for her!  She is happy to be back in Switzerland, where she can do all her hobbies and be closer to her family. She was always inspired by her dad, his career, and what he was able to achieve. Her dad has always supported her in everything she has done, and she has always been inspired by him. At HEMEX, we believe she is on the right path, and she has a bright future. We truly appreciate her new brilliant ideas and foreseen professional success in her career.

As a part of our diversity series, we asked Arthur to sum up Laurène in one word. He said that for him, Laurène is ENTHUSIASTIC.

About HEMEX

HEMEX was founded as a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. We specialize in supporting early-stage start-ups, and we offer tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. We are now gaining fast recognition, and this is partly because we are transforming the culture by seamlessly bridging the gap between investors and entrepreneurs.

Who are the Top 100 Swiss Start-ups in 2020?

The Top 100 Swiss Start-up celebrated a very special edition yesterday. Besides being their 10th anniversary edition, for the first time, the award show was live-streamed for safety reasons, and ran perfectly smoothly!

 

At Hemex, we are very proud of our five portfolio start-ups that have made it onto the Top 100 Swiss Start-up. For a Start-up to get onto this list is a big honour because they are selected by a panel of 100 leading investors and experts. Keep an eye on them this year because they are going to be in the spotlight of innovation! 

Firstly, we would like to congratulate ASPIVIX and Scailyte for being in the top 100!

Aspivix is developing the next-generation surgical instrument for gentle and modern gynaecological procedures. Aspivix’s device is a gentle vacuum suction-pad applied to the cervix to steady it during gynaecological procedures. Pain is minimized, there is no bleeding, the risk of cross-contamination is eliminated, and the whole experience is less traumatic.

 

Scailyte logo

Scailyte is a data-driven biomarker discovery company that detects complex disease patterns from single-cell data at the onset of disease. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. 

 

Secondly, we would like to congratulate Annaida Technologies for being in the top 50! Annaida was also second in the Top 3 best Newcomers for the Top 100 Start-up’s 2020.

Annaida Technologies logo

Annaida Technologies is the first high-tech company start-up bringing magnetic resonance to embryo scale. Annaida is an EPFL spin-off that is harnessing a technology that is delicate enough to use on a human embryo. The start-up’s device performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. 

 

Thirdly, huge congratulations to our portfolio company Resistell AG for being in the top 10! Resistell was also in the top 3 best Biotech start-ups.

Resistell logo

Resistell is a EPFL spin-off that has been able to successfully achieve reliable antibiotic susceptibility results up to 100 times faster than conventional, culture-based methods. Resistell’s test is based on the measurement of living bacteria vibrations from the sample by using nanosensors. This reduces the time-to-result from several hours or days to less than two hours. Patients can be treated with optimal medication from day one. 

 

TOP 100 Swiss Start-ups ranking brings the best investors together with the best start-ups. It’s the most prestigious start-up award in Switzerland. Being among the TOP 10 is a huge recognition and was definitely unexpected, especially given that we were incorporated only two years ago. For Resistell it’s a huge motivation to work even harder now to climb up the list next year!                                                                                                   – Danuta Cichocka, CEO of Resistell. 

 

Finally, a special mention to Sleepiz, who won the public vote for medtech Start-ups!

Sleepiz logoSleepiz has produced innovative technology that will revolutionize the medical community. It is a patient-centered simple device that you can put on your bedside table. Their advanced equipment operates without cables and captures vital signs without touching the patient. With advanced statistical models and artificial intelligence, the device provides accurate analysis and insights to diagnose sleep disorders at home. 

 

As we mentioned before, for a Start-up to get onto this list is a big honour.The jury are all specialists in the start-up sector and chooses the 100 start-ups with the most significant potential in Switzerland. This is how it works; each expert chooses ten start-ups and ranks them from one to ten.  Subsequently, the start-ups with the highest scores are the ones that made it onto the list.

Top 100 Swiss Start-up Award brings the most innovative Swiss Start-ups into the public eye. This award is not only for Swiss Start-ups but also international companies. In the 10th anniversary edition, the first three positions went to Cutiss (1st), Wingtra (2nd), and Piavita (3rd). Additionally, the Public Voting award went to Acatena. At Hemex we wanted to contratulate these four start-ups, we believe they have a very promising and ground-breaking future. Therefore, we suggest you also keep an eye on them as well!

 

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

The next step in heart bypass technology

About 1,000,000 patients undergo highly invasive heart bypass surgery yearly. Our portfolio company AMT Medical has developed a unique technology to enable a safe, affordable, and minimally invasive coronary bypass surgery.

 

Every single day, millions of people suffer from Coronary Artery Disease (CAD). As the name suggests, it is a disease of coronary arteries, where usually these arteries get completely or partially blocked due to cholesterol deposits. CAD is the most common type of heart disease, and it is the leading cause of death in many countries of the world. This disease can have long and stable periods but might also become unstable at any time. CAD is a serious progressive and chronic disease that needs to be controlled and checked periodically.

In severe cases, Coronary Artery Bypass Graft (CABG) might be needed. CABG is a surgical procedure used to treat CAD. Coronary Artery Bypass Graft is performed when there is a blocked artery in the heart, or in emergency situations, such as heart attack if there is no response to other treatments. This procedure is highly invasive and is associated with long recovery times and serious complications, mainly due to the opening of the chest and stopping the beating of the heart during the surgery; these conditions could lead to complications during or after the surgery. 

AMT Medical is developing a unique coronary bypass system based on a technique used for similar indications in the brain. ELANA (Excimer Laser-Assisted Non-Occlusive Anastomosis), the sister company from AMT, introduced this procedure to the market for neurosurgery. Now AMT it’s applying it for CABG. ELANA enables a safe, affordable, and easy-to-use minimally invasive Coronary Artery Bypass Graft securing shorter recovery time and fewer complications. 

The AMT technique enables ELANA Coronary Bypass to be performed through small holes in the chest. Therefore the need to open the chest is not necessary anymore; neither is the heart-lung machine nor the suturing to hold the graft in place. For the patient, this means fewer chances of infections, internal bleeding, stroke, and much shorter recovery time. 

The European Commission awarded last year a consortium led by AMT Medical, including HEMEX, with a €2.2 M grant under its “Fast-Track to Innovation (FTI)” program. Under this proposal, HEMEX is in charge of planning, coordinating, and executing the multicentric, pan-European study in order to obtain the CE-mark for the Excimer Laser-Assisted Non-Occlusive Anastomosis (ELANA) Heart Bypass System in Patients undergoing Coronary Artery Bypass Grafts (CABG).

For more information on the progress of this life-changing therapy, please contact franziska.stemmler@hemex.ch

Co-funded by the Horizon 2020 Framework Programme of the European Union and the Grant Agreement (GA) No. 869922. 

About AMT Medical

AMT Medical is a pre-clinical stage medical device company from the Netherlands. Together with the UMC Utrecht is developing a unique coronary bypass system. AMT’s motivation is to develop simple ‘best in class’ coronary bypass technology through keyholes. The new standard, with lower costs for society, fewer complications, and a faster recovery for the patient.

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Swisscom StartUp Challenge – Pitch your 5G Case and Win!

This year, the program is aimed at start-ups and research teams whose solutions are based around the latest 5G mobile generation.

 

What is this year’s theme?

After seven successful editions, this year’s Swisscom StartUp Challenge has a unique theme for the first time and has taken on an international dimension. The program is aimed at start-ups or research teams whose solutions are based on the latest 5G mobile generation. It provides a unique chance for tech start-ups and research teams to pitch their products or functioning prototypes to an expert jury and win a weeklong Exploration Programme in Switzerland with a 5G innovator.

Who can participate?          

– Tech start-ups with a clear competitive edge that are ready to enter or have already entered the market.

– Research projects relating to 5G applications based, for example, at universities and other higher           education institutions. 

What can the ten finalists expect?

  • Participation in the pitch event on 17 December 2020 at the Swisscom Pirates Hub Zurich or via telepresence
  • Pitch training with personal feedback from venturelab experts to help prepare for the final on 3 December 2020
  • Analysis of business cooperation with Swisscom and investment by Swisscom Ventures
  • Easy access to the Swisscom and programme partner networks (Venturelab, Ericsson, Qualcomm)
  • Visibility thanks to inclusion in publicity surrounding the Swisscom StartUp Challenge

What can the five winners expect?

  • Working with the latest 5G architectures where E2E testing can take place
  • Access to the Swisscom 5G network at a range of locations 
  • Access to 5G smartphones, hotspots, tablets, laptops, existing Swisscom services, and testing tools
  • Support/mentoring by 5G experts from Swisscom and partner firms/program partners
  • Further development of marketing and sales skills
  • An unforgettable week in Switzerland including a visit to the Swiss Federal Institute of Technology and Swiss business/technology innovators

Where to apply?

Let’s shape the future together with the Swisscom StartUp Challenge! Apply with your 5G use case before 11 October HERE.

For general questions, contact Jennifer Adam (jennifer.adam@swisscom.com)

 

About the Swisscom StartUp Challenge

The Swisscom StartUp Challenge was launched in 2013. To date, they have been able to accompany numerous start-ups on their journey. They believe in the innovative strength of start-ups, and this year they are supporting 5G-related research projects. More at Swisscom.

 

About Hemex

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.